- Home
- EIC vs ENTA Comparison
EIC vs ENTA Comparison
Compare EIC & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- ENTA
- Stock Information
- Founded
- EIC N/A
- ENTA 1995
- Country
- EIC United States
- ENTA United States
- Employees
- EIC N/A
- ENTA N/A
- Industry
- EIC Finance/Investors Services
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- ENTA Health Care
- Exchange
- EIC Nasdaq
- ENTA Nasdaq
- Market Cap
- EIC 250.6M
- ENTA 245.4M
- IPO Year
- EIC 2019
- ENTA 2013
- Fundamental
- Price
- EIC $16.46
- ENTA $11.07
- Analyst Decision
- EIC
- ENTA Buy
- Analyst Count
- EIC 0
- ENTA 4
- Target Price
- EIC N/A
- ENTA $20.00
- AVG Volume (30 Days)
- EIC 116.0K
- ENTA 113.5K
- Earning Date
- EIC 11-14-2023
- ENTA 11-25-2024
- Dividend Yield
- EIC 13.63%
- ENTA N/A
- EPS Growth
- EIC N/A
- ENTA N/A
- EPS
- EIC 0.80
- ENTA N/A
- Revenue
- EIC N/A
- ENTA $71,960,000.00
- Revenue This Year
- EIC N/A
- ENTA N/A
- Revenue Next Year
- EIC N/A
- ENTA $5.14
- P/E Ratio
- EIC $20.31
- ENTA N/A
- Revenue Growth
- EIC N/A
- ENTA N/A
- 52 Week Low
- EIC $13.00
- ENTA $8.08
- 52 Week High
- EIC $16.48
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- EIC 61.21
- ENTA 42.54
- Support Level
- EIC $15.88
- ENTA $10.84
- Resistance Level
- EIC $16.30
- ENTA $11.83
- Average True Range (ATR)
- EIC 0.25
- ENTA 0.57
- MACD
- EIC 0.06
- ENTA -0.07
- Stochastic Oscillator
- EIC 79.75
- ENTA 13.53
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.